The hard reality is Big Pharma (and therefore investors) is/are only interested in the "lead indication", they are not interested in the "pipeline". So if the lead indication fails, interest dies very quickly, and the timeline & cost to new data extends.
My issue with this company is they listed touting BME (oh, and lets not forget Exosomes - where have they gone?), then switched their focus to hay fever. RRV has also only been a very recent addition. Suspect the reason is the end market for BME is not that large/of interest to Big Pharma.
At $0.33c this company is still capped at $34m - think about it - and their drug is repurposed, off patent and been around for 60-years.
Ann: Hay Fever Trial Update, page-9
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.0¢ |
Change
0.060(13.0%) |
Mkt cap ! $82.30M | |||
| Open | High | Low | Value | Volume |
| 47.0¢ | 56.0¢ | 40.0¢ | $4.475M | 8.971M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 12150 | 49.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.0¢ | 39994 | 1 |
View Market Depth
| Last trade - 16.10pm 26/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
